Ocriplasmin: A Promising Option for Vitreomacular Adhesions

Dr. Julia Haller from Wills Eye Institute comments on ocriplasmin’s potential to become the first pharmacologic option to treat symptomatic vitreomacular adhesions, and how it could affect practice.
Medscape Ophthalmology

Full Story →